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Direct-to-consumer (DTC) testing provides consumers access to genetic testing without 
involvement or advice from a genetics specialist. By sending a saliva sample to a DTC company, 
consumers can have their DNA analyzed for information on ancestry, paternity, disease-related 
risks, and many other heritable traits. Approximately 246 companies offer DTC testing with 71 
companies offering health-related testing, including 23andMe, AncestryDNA, and Helix 
(Phillips, 2016). DTC testing has recently expanded to include reports on diet, exercise, carrier 
testing, and pharmacogenetics (Niemiec, Kalokairinou, & Howard, 2017). While this expansion 
has increased consumer access to genetic interpretations, these reports can often provide a false 
sense of security and rarely cover enough genetic information to make significant interpretations 
about disease risk. 
To provide an example of difficulties in navigating DTC test results, imagine ordering 
testing from a company like 23andMe. You open an email link and get a test report that indicates 
that you do not have any of the 3 BRCA mutations that 23andMe identifies. You feel relieved and 
might be less concerned about following recommended cancer screenings, typically 
mammograms for women and prostate cancer screenings for men (Bellcross, Page, & Meaney-
Delman, 2012). You might also have a lower perceived risk than your actual cancer risk. Without 
reading and understanding the full report, you may not realize that most cancers caused by BRCA 
mutations are not caused by the 3 mutations that 23andMe looks for, and that these mutations are 
mostly relevant to people with Ashkenazi Jewish ancestry. If you do not have Ashkenazi Jewish 
ancestry, this information is likely irrelevant to your BRCA-related cancer risk. This scenario 
highlights a common disconnect between DTC test results and impressions of disease risk. If you 




had a strong family history of breast cancer, further genetic testing might be medically advisable. 
If you met with a genetic counselor, after looking at your family history, they might recommend 
full sequencing of the BRCA1 and BRCA2 genes, PALB2, and other genes associated with 
increased breast cancer risk (Miki et al., 1994; Rahman et al., 2007; Wooster et al., 1994). This 
level of detail can help provide a more comprehensive view of risk and is built upon personal 
ethnicity and family history. With the guidance and involvement of a genetic counselor, the 
meaning and possible impact of direct-to-consumer testing results can be clearly explained, and 
possible follow-up testing can be provided.  
Currently, direct-to-consumer testing does not typically include involvement or guidance 
from genetic counselors. Consumers order a genetic test online and then view their results. If 
consumers hope to make health-related decisions based on testing, involving a genetics 
professional can be a valuable way to help interpret and explain limitations of DTC results. 
While studies have investigated the uptake of genetic counseling after DTC testing and some 
outcomes related to understanding test results after counseling, changes in attitudes and 
understanding of specific results provided in DTC reports have not been examined before and 
after genetic counseling sessions. The purpose of this study is to examine genetic counselors’ 
opinions about how genetic counseling sessions may change an individual’s understanding, 
perceived value, and anxiety related to direct-to-consumer (DTC) and/or patient-initiated genetic 
testing. With the guidance of a genetic counselor, health advice can be tailored to the patient and 









Motivations for ordering DTC testing 
Consumers often order DTC testing with the hope of gaining information relevant to their 
health, ancestry, and to find blood relatives. A ranking of motivations for pursuing DTC-PGT 
(personal genomic testing) from 23andMe and Pathway Genomics found that top motivations 
were personal disease risk, desire to improve health, and finding out about personal medication 
response (Koeller, Uhlmann, Carere, Green, & Roberts, 2017). Since DTC test results can 
influence health management, it is important for consumers to understand the limitations and 
values of DTC genetic testing reports as they relate to interpreting disease risk.  
Variant Detection 
For individuals hoping to gain health-related information, DTC testing can have limited, 
incorrect, or misleading information. DTC tests typically scan for variants associated with 
diseases or specific traits that have been identified via genome-wide association studies (GWAS) 
(Bellcross et al., 2012). These studies look at single nucleotide changes, or SNPs (single 
nucleotide polymorphisms), that are associated with a given disease by comparing individuals 
from a specific population with and without a disease to people with and without a given 
nucleotide change. Variants identified via GWAS are not typically generalizable and DTC 
results do not incorporate familial risk (Bellcross et al., 2012). The problem with applying these 
studies to the general public is that typically SNPs associated with a specific disease are relevant 
to a small portion of the total population, like how a set of 3 common BRCA1 and BRCA2 
variants are relevant to individuals with Ashkenazi Jewish ancestry and are considered founder 
mutations (Bellcross et al., 2012). SNPs that are identified in DTC testing typically have odds 
ratios of less than 1.5% for common diseases (Bellcross et al., 2012). If a DTC test looked for an 
SNP associated with colon cancer, which had an odds ratio of 1%, a test indicating that someone 




did not have this SNP would provide almost no information on this person’s colon cancer risk. In 
this case, 99% of colon cancers are not caused by the mutation identified in testing. This 
highlights the limited generalizability of most genetic testing for SNPs. 
Ambry genetics recently ran a study on variants associated with diseases that were 
identified in reports from DTC companies (Tandy-Connor et al., 2018). Testing to confirm the 
DTC results came from medical providers, typically genetic counselors, medical geneticists, or 
oncologists, who had ordered testing to confirm the variants identified via DTC genetic testing. 
Of the 49 patients tested, 43 (87.8%) of them received reports indicating that they had variants 
associated with cancer risk caused by mutations in genes including BRCA1 and BRCA2, 
CHECK2, TP53, and ATM. After full gene sequencing to look for variants in the genes reported, 
40% of the DTC results were found to be false positives. This means that 4 out of 10 patients 
who were given reports claiming they had a disease-causing variant did not actually have the 
variant. These findings indicate a significant problem with quality and interpretation of genetic 
testing by DTC companies. In addition, 8 variants were classified as increasing disease risk by 
either DTC or third-party interpretation (TPI) analysis in the genes ATM, BRCA1, BRCA2, 
COL3A1, and COL5A1. Pathogenic variants in the genes ATM and BRCA1/2 are associated with 
increased risk for breast, ovarian, and prostate cancer, while pathogenic variants in COL5A1 and 
COL3A1 are associated with the connective tissue disorder Ehlers-Danlos syndrome. These 
variants were identified as benign, or not causing disease, by databases including 1000 Genomes 
and Ambry (Auton et al., 2015; Tandy-Connor et al., 2018). DTC testing often provides 
inaccurate data that may be irrelevant to the consumer ordering testing. 
While the previous study indicates high false positive rates in DTC testing, we do not 
know their false negative rates. A false negative report would falsely indicate that a patient does 




not have a risk-predisposing mutation, when they do have a mutation associated with disease 
risk. When patients may act based on DTC test results, companies’ incorrect negative or positive 
results can have serious consequences. In the case of a false negative, someone may think they 
have reduced risk based on a result indicating that they do not have any of the screened 
mutations associated with cancer.  If this patient has a mutation that increases cancer risk, an 
early cancer could be missed. For healthcare providers unfamiliar with genetics, seeing a DTC 
test result that indicates increased or decreased risk could also guide how they treat patients, or 
even their recommendations for preventative surgeries. If a patient presents a test report 
indicating they have a BRCA1 or BRCA2 mutation, a doctor may follow guidelines of 
recommending prophylactic bilateral mastectomy and salpingo-oophorectomy (removal of the 
ovaries and fallopian tubes) without confirmatory testing (Ludwig, Neuner, Butler, Geurts, & 
Kong, 2016). Overall, direct-to-consumer testing has limited value and reliability.  
Consumer Expectations from DTC results 
In a study which surveyed 23andMe and Pathway Genomics customers, PGEN 
participants reported lower genetics self-efficacy scores after receiving DTC results (Carere, 
Kraft, Kaphingst, Roberts, & Green, 2016). Genetics self-efficacy was assessed using a 5-item 
Likert scale, with consumers rating how strongly they agreed with statements like “I am 
confident in my ability to understand information about genetics” and “I have a good idea about 
how genetics may influence risk for disease generally” on a scale from 5 (all strongly disagree) 
to 35 (all strongly agree). There was a significant decrease in genetics self-efficacy scores from 
baseline to 6-months after viewing DTC test results. This decrease may reflect decreased 
confidence in understanding and interpreting the relevance of genetic information to health after 
viewing complex, lengthy results. This also likely indicates that consumers overestimate their 
ability to interpret and understand genetic information and their confidence changes after 




attempting to interpret results on their own. This decrease highlights the value of genetics 
specialists in helping patients interpret and understand genetic testing results, as well as 
explaining some of the limitations of DTC testing. In addition, this study included a series of 
nine true-false questions to gauge genetics knowledge. Consumer baseline scores in genetics 
knowledge were very high and increased slightly 6-months after viewing results. With this small 
increase in genetics knowledge, it is difficult to gauge whether the change in genetics knowledge 
resulted from subjects’ increased understanding of genetics after viewing and understanding test 
results, or from other variables including pretest sensitization, ceiling effects, and maturation. In 
this case, maturation would describe a general increase in public genetics knowledge during the 
6 months after respondents completed baseline surveys. Pretest sensitization refers to a change in 
test scores because respondents may have learned answers after seeing the baseline survey. The 
authors also acknowledge the likely influence of a ceiling effect, since the average baseline score 
of 8.15 was very close to the maximum score of 9.  
Further analysis following the PGEN study revealed that perceived risk of breast, 
prostate, and colorectal cancer increased when DTC results reported elevated risk, while 
perceived risk decreased when DTC results reported that an individual had an average population 
risk  (Carere et al., 2015). With lung cancer, perceived risk increased, regardless of whether 
results indicated an average or increased cancer risk. Having a decreased perceived risk of 
different types of cancer can have negative health consequences if patients decide to avoid 
preventative screenings and have a false sense of low risk.  
Genetic Counseling Following DTC Testing 
The PGEN study also surveyed individuals to help understand motivations for pursuing 
genetic counseling following DTC testing. Out of 1,026 individuals enrolled in the study, only 
4% sought genetic counseling. Compared to participants who did not seek genetic counseling, 




participants who pursued genetic counseling tended to report poorer health, were more likely to 
have had previous genetic counseling, were younger, and more likely to have children. They also 
tended to report higher uncertainty about what test results meant about personal risk (60% of GC 
seekers vs 27.2% of non-GC seekers) (Koeller et al., 2017). 
Unlike the PGEN study, the Scripps Genomic Health Initiative enrolled patients in a DTC 
PGT program which included no-cost access to genetic counseling services (Darst, Madlensky, 
Schork, Topol, & Bloss, 2013). Consumers would receive test results from Navigenics, a DTC 
company which offered free genetic counseling services to help explain results to consumers; 
Navigenics was acquired by Life Technologies in 2012 and no longer offers DTC testing 
(Dorfman, 2013). Among the 1,325 participants, 14.1% spoke with a genetic counselor; when an 
active effort was made to contact patients about GC services via phone or email, utilization rates 
of GC went up to 27.3% (Darst et al., 2013). When asked about reasons for meeting with a 
genetic counselor, 43.9% reported wanting to take advantage of a free service and 42.2% wanted 
more information on risk calculations. After genetic counseling, 85% reported that genetic 
counseling helped them improve their understanding of test results and 75.5% reported that it 
improved their understanding of genetics overall. Of those who did not pursue genetic 
counseling, 55.6% believed that they already understood their results and approximately 20% 
reported wanting to use genetic counseling but were ‘too busy’. This indicates that even when 
genetic counseling services are provided at no cost, utilization rates following DTC testing are 
low. However, amongst patients who see a genetic counselor, they generally report very high 
satisfaction and find value in the interpretation and explanations provided by genetic counselors.  
  




Results with high psychological burden 
With an increasing number of DTC companies providing information on disease risk 
relating to serious conditions such as breast cancer, Alzheimer’s, and Parkinson’s, genetic testing 
companies have a responsibility to offer support. Without pre-test counseling, consumers may 
not have considered how they might be affected by a result indicating that they are at increased 
risk of developing all the diseases analyzed via DTC testing. They may not have thought through 
how a positive result might affect their relatives and children, and their own mental health. 
Consumers may be left with burdensome results that can shake up their world, with nothing more 
than an email link to information on the disease and the mutation that they carry. When 
providing such burdensome results, DTC companies should make access to pre- and post-test 
genetic counseling available to consumers (Middleton, Mendes, Benjamin, & Howard, 2017).  
Considering that studies on positive genetic testing results have found increased anxiety and 
depression amongst patients after disclosure of the genetic test results, an individual who can 
provide resources and tools for support is valuable to navigating the emotional distress that 
positive results can bring (Benusiglio et al., 2017; Brédart et al., 2017; Scherr, Christie, & 
Vadaparampil, 2016).  
Ancestry Testing 
Ancestry testing has been used to estimate pan-ethnic heritage and users can often opt 
into receiving information on relatives identified via ancestry testing. These ethnicity estimates 
are based on current native and indigenous populations, and similarities to their DNA is used to 
estimate a person’s geographic ancestry (Kirkpatrick & Rashkin, 2017). While these can often 
provide accurate continental information, estimates of specific regions within a country are likely 
inaccurate. These estimates are unable to account for large migrations and population 
bottlenecks, including epidemics or famine. For these reasons, the ‘native population’ DNA used 




as a proxy for pan-ethic origin today may have originated or moved from other locations and 
likely interbred with populations from other regions. For these reasons, test results with ancestry 
information are likely unreliable if they estimate ancestry within a small geographic area. 
Individuals who order ancestry testing through companies like Family Tree DNA, 
23andMe, Ancestry DNA, and National Geographic Geno 2.0 can download raw data VCF files, 
which can be uploaded for third-party interpretation. Third-party interpretation (TPI) companies, 
such as Promethease, Interpretome, and Livewello provide SNP analysis of the data file from 
DTC testing for additional information on ancestry, disease risk, metabolism, and other traits. 
Third party interpretation (TPI) of data from DTC test results rarely involves complete informed 
consent, medical oversight, or accurate interpretation (Badalato, Kalokairinou, & Borry, 2017). 
While the ability to know as much as possible about the data generated from a DTC test seems 
valuable, unfortunately these reports can often be misleading or incorrect.  
Data Privacy  
Many consumers are unaware of how their data will be used by DTC and TPI companies. 
In a review of a Canadian DTC company websites, researchers found that 67% of the companies 
reviewed did not provide adequate information for consumers to understand how their data might 
be used (Christofides & O’Doherty, 2016). Many DTC companies sell consumer information to 
pharmaceutical companies to use with the intention of developing drugs tailored to disease risk. 
In a study of DTC companies which offer health or ancestry testing, researchers reviewed 
companies for privacy policies or terms of service. Out of 30 reviewed companies, only 13% 
stated that they would not use consumer data for research or other purposes and 30% of the 
companies indicated that they planned to use consumer data for health-related research  
(Laestadius, Rich, & Auer, 2017).  




Recently, 23andMe has partnered Genentech, which has paid $10 million with the 
interest of gaining access to DNA sequencing information relevant to Parkinson’s disease drug 
development (Mullard, 2015). The partnership includes plans to perform full genome sequencing 
on 3,000 patients with Parkinson’s disease. With widespread sales of personal genomic data, the 
informed consent process should be thorough and clearly explain to consumers that their data is 
not private. Unfortunately, many consumers order direct-to-consumer with misperceptions about 
the privacy of their data due to an inadequate informed consent process.  
Patient-Initiated Testing 
Patient-initiated testing involves patients seeking out and ordering genetic testing, 
typically through an online platform. Genetic testing may be ordered to understand hereditary 
cancer risk or reproductive risks through carrier screening. Generally, patients pay on a cash 
basis for a genetic test of their choice. Their self-reported medical and family history is reviewed 
by a clinician before the test is ordered. Then the patient provides a saliva or buccal sample for 
genetic testing. Genetic testing results can typically be viewed through an online portal, often 
with the option to discuss results with a genetic counselor.  
Some patient-initiated testing includes genes on the ACMG (American College of 
Medical Genetics) 59 list, which is a list of genes for which reporting findings on clinical exome 
or genome sequencing is recommended (Kalia et al., 2017). These genes are considered 
medically actionable, meaning that patients with pathogenic mutations in any of these genes have 
possible screening or treatment options available for the associated condition. As an example, 
genes associated with Lynch Syndrome, MLH1, MSH2, MSH6, and PMS2, have management 
recommendations including colonoscopies every 1-2 years, starting age 20-25 or 2-5 years 
before earliest diagnosis of colon cancer in a family (National Comprehensive Cancer Network, 
2019).  




Genetic Counselor Involvement 
With the limited relevance to healthcare and poor reliability of DTC test results, it can be 
valuable for consumers to meet with genetic counselors to clearly explain the limitations of 
testing and to identify possible health-related risks based on family history. Genetic counselors 
can also provide possible follow-up testing with certified labs when disease risk based on family 
history or DTC testing suggests that additional testing may be useful. Since false positive rates in 
DTC testing are high, it is very important to confirm variants reported via DTC testing or TPI 
through certified labs with full gene sequencing. Since genetic counseling demand currently 
exceeds the availability of genetic counselors, access to counseling about DTC testing results 
will likely depend on alternative models of GC. These models include telegenic, telephone 
counseling, and group counseling (McCuaig et al., 2018). Telegenic counseling involves meeting 
with patients via video conference, similar to skype. Group counseling sessions involve 
presenting to a group of individuals about disease risk and genetic testing, often with the 
opportunity to meet one-on-one following a group presentation and discussion. Although one-on-
one counseling sessions typically have a more personal and patient-centered feel, alternative 
models are currently necessary to meet patient demand. For individuals who live far from a clinic 
or hospital with genetic counselors available, telehealth may be the only option. To meet with 
patients regarding DTC test results, group counseling sessions could provide a high-impact way 
to explain DTC test results and some of the limitations in testing. Following a group counseling 
session, patients could meet one-on-one with counselors to discuss the findings within their 
personal DTC report. Genetic counselors can help navigate DTC results and suggest certified 
labs to run follow-up analyses 
Previous studies have not done an in-depth comparison of consumers’ understanding of 
test results, genetics understanding, and feelings of anxiety or depression resulting from DTC 




test results. This study seeks to understand the change in consumer attitudes and understanding 
of test results by surveying genetic counselors. I expect that genetic counselors see increased 
understanding of limitations in DTC test results, increased genetics knowledge, and reduced 
anxiety and depression related to testing results after genetic counseling sessions regarding DTC 
results.  
  






Materials and Methods 
Survey Distribution and Content 
This study involved distributing a survey via email listserv to the National Society of 
Genetic Counselors’ (NSGC) members through their Student Research E-blast service. 
Participants were at least 18 years old and genetic counselors. Respondents were asked for basic 
demographic information including ethnic origin, age, gender, zip code of practice, and area of 
practice (clinical, industry, or research). The survey asked about impressions of patient 
understanding and feelings related to DTC and patient-initiated genetic testing results. Examples 
of questions included level of agreement with statements like ‘Before counseling, patients have 
anxiety related to their DTC genetic testing results’ and ‘I am in favor of consumers being able 
to self-order clinical testing of larger panels, including genes outside of the ACMG 59 gene 
list.’ A copy of the survey is available in Appendix A. The survey asked for impressions of how 
consumers feel about their DTC results before compared to after genetic counseling sessions. 
The survey also asked about consumer anxiety, understanding of the medical significance of 
results, limitations of results, how genetic variants influence health and disease risk, and how 
well consumers understand their results report.  
Counselors were asked on a 5-item Likert scale from ‘strongly disagree’ to ‘strongly 
agree’ about impressions of patient-initiated and DTC testing. Questions included whether they 
support consumers being able to self-order genetic testing of the ACMG 59 gene list, self-order 
large panels including genes outside of the ACMG 59 list, whether pre-test counseling is 
necessary to have informed consent, whether speaking with a genetic counselor regarding results 




should be optional, and level of concern regarding the expansion of DTC and patient-initiated 
testing.  
Lastly, a series of open-ended questions asked counselors to describe what information 
regarding DTC testing and results consumers find most helpful, the misconceptions consumers 
have surrounding testing, challenges in dealing with DTC results, and experiences with patient-
initiated testing.  
Data Cleaning 
Data cleaning was performed in order to detect invariant or careless respondent answers 
and ensure that all participants qualified to participate in the study. All 60 respondents consented 
to participate in the study. Of the 60 respondents, 6 (10.0%) failed to provide any information 
after providing consent and were thus removed from the dataset, resulting in a final sample of 54. 
The amount of time respondents spent completing the survey was examined to rule out 
responses from bots. The survey took participants, on average, 31.0 minutes to complete (SD = 
86.4), with examination of shortest completion time (0.8 minutes) and longest completion time 
(9.6 hours) showing several outliers. Visual inspection of subjects’ responses revealed that those 
who completed the survey extremely quickly simply left many questions blank. These subjects 
were left in the dataset, as their responses appeared to reflect good faith efforts from human 
respondents (i.e. not near-instantaneous responses to all questions by bots), and missing data is 
simply excluded from pertinent analyses. Extremely long response times (> 1 hour) were 
observed for 4 respondents, but all 4 responses appeared to represent good faith efforts to 
respond to the survey, and could be explained by practices such as opening the survey in another 
tab and forgetting about it. As a result, no subjects were removed due to completion times. 




Examination of subject’s written responses, histograms of numeric variables, and 
frequency tables of categorical variables failed to detect any evidence of careless, malicious, or 
invariant responses, so no additional responses or subject were removed from the dataset. 
Data Analyses 
Study data were collected and managed using Qualtrics. Data analysis was performed 
using SPSS Software for independent samples t-tests, chi-square tests of independence, and 
paired samples t-tests. For statistical analysis, p < 0.05 was considered a significant difference.  
Independent samples t-tests were run to compare differences in age, percentage of genetic 
counseling sessions including discussions of direct-to-consumer test results, and percentage of 
genetic counseling sessions including discussions of patient-initiated test results between clinical 
and industry/research/other specialties. Chi-square tests of independence were used to compare 
differences in ethnicity and gender between clinical and industry/research/other specialties. 
Paired samples t-tests were run to report perceived differences in patient outcomes before and 
after counseling sessions discussing direct-to-consumer test results. Independent samples t-tests 
were run to compare projected changes in patient outcomes surrounding direct-to-consumer test 
results between clinical and non-clinical genetic counselors. Lastly, independent samples t-tests 
were used to compare clinical and non-clinical genetic counselor differences in attitudes toward 
direct-to-consumer and patient-initiated genetic testing.  
  








Table 1. Demography of Responding Genetic Counselors (n = 53 – 54) 
 
* Comparisons between Clinical counselors and Industry/Research/Other counselors conducted via independent samples t-tests 
or chi-square tests of independence, where appropriate.  
 
As shown in Table 1, limitations in the demography of respondents warrant consideration 
and should be kept in mind for the remainder of the analyses discussed below. Specifically, 
respondents to this survey were entirely female and overwhelmingly white, with the majority 
(87.0%) of respondents indicating working in a clinical setting. Amongst respondents from 
Industry, Research, or Other settings, none of their counseling sessions included discussions of 
DTC or Patient-initiated test results. Amongst clinical genetic counselors, about 8% of 
counseling sessions included discussion of DTC testing and 3% included discussions of patient-
initiated testing. There was not a significant difference in percentage of counseling sessions 
involving discussion of DTC vs Patient-initiated testing between clinical and 
industry/research/other counselors. Percentage of counseling sessions including discussions of 
patient-initiated testing were significantly higher amongst clinical genetic counselors. In 
addition, respondents exclusively from Industry, Research, or Other settings were significantly 
older than respondents exclusively working in Clinical settings. 
  




Genetic counselor attitudes towards direct-to-consumer and patient-initiated testing 
Figure 1. Agreement* with Statements Regarding Patient-Initiated and DTC Testing (n = 41 - 42) 
 
* Note: Agreement refers to a score of 5 “strongly agree” or 4 “agree” on a 5-pt Likert-type scale 
 
Level of agreement with statements regarding direct-to-consumer and patient-initiated genetic 
testing was outlined in Figure 1 to show genetic counselor attitudes towards genetic testing. 
Agreement was noted when counselors selected ‘agree’ or ‘strongly agree’ on a 5-point Likert-
type scale. Most genetic counselors surveyed agreed that pre-test counseling with a genetic 
counselor is necessary for consumers to have informed consent before ordering patient-initiated 
testing. A majority also expressed concern about the expansion of patient-initiated testing and the 
evolving role of genetic counselors. Over 80% agreed that as DTC and patient-initiated testing 
options expand, the need for genetic counselors is going to increase. Fewer than half of genetic 
counselors supported consumers being able to self-order clinical testing of the ACMG 59 gene 
list, and even fewer supported consumers being able to self-order clinical testing of larger panels, 
including genes outside of the ACMG 59 gene list. About one third of genetic counselors agreed 
that speaking with a genetic counselor after receiving patient-initiated test results should be 
optional. Just under half of genetic counselors were concerned about how the role of clinical 
genetic counselors will change as DTC and patient-initiated testing options expand. Fewer than 
10% of genetic counselors agreed that consumers understand the possible test results before 




ordering patient-initiated testing and that consumers ordering patient-initiated testing understand 
the health-related implications of a negative result. Fewer than 20% of genetic counselors agreed 
that consumers ordering patient-initiated testing understand the health-related implications of a 
positive result and how patient-initiated test results apply to family members. None of the 
genetic counselors surveyed felt that consumers understand the implications for long-term care, 
life, and disability insurance before ordering patient-initiated testing. 
 
Perceived changes in patient outcomes with genetic counseling 
Table 2. Summary of Paired Samples t-tests Comparing Projected Changes in Patient Outcomes Surrounding Direct to 
Consumer Test Results (n = 38 - 42) 
 
Perceived changes in patient outcomes with genetic counseling regarding DTC results, 
are outlined in Table 2. This comparison was made through a series of questions asking for the 
level of agreement with statements such as ‘before genetic counseling consumers have anxiety 
related to their DTC genetic testing results’. A second version of this question was also asked 
regarding patient anxiety after a genetic counseling session. These pairs of questions regarding 
consumer attitudes and understanding were used to compare changes before and after counseling 
in consumer understanding of medical significance of DTC results, understanding of the 
limitations of DTC testing, understanding of how genetic variants can affect health and disease 
risk, and understanding of their DTC result reports. A series of paired samples t-test revealed that 
respondents estimate that, following genetic counseling regarding direct to consumer test results, 
there are statistically significant improvements in all patient outcomes except for anxiety (p’s < 
0.05). Regarding the clinical significance of the reported statistically significant differences, all 




statistical significant comparisons had Cohen’s D scores of greater than 0.8, Cohen’s suggested 
cut-point for large effects (Cohen, 1988). This suggests that the anticipated changes in clients 
scores is not only statistically significant, but also of a clinically meaningful magnitude. 
Perceived changes in patient outcomes by area of practice 
Table 3. Summary of Independent Samples t-tests Comparing Projected Changes in Patient Outcomes by Clinical versus Industry 
GCs (n = 38 – 42) 
* Calculated as Posttest – Pretest score. 
 
In order to compare estimated changes in patients’ outcomes due to genetic counseling by 
clinical respondents compared to non-clinical ones, change scores (post-pre) were calculated for 
each of the variables in Table 2. As shown in Table 3, no statistically significant differences were 
observed between clinical and non-clinical respondents’ estimations of how much patients’ 
scores would change from before genetic counseling to after genetic counseling (p’s > 0.05). It is 
worth noting that among the non-clinical respondents, an already small group (n = 7), only 4-5 
offered ratings on these variables, reducing their already small sample size further. Interestingly, 
while no results were statistically significant, two comparisons showed effect sizes greater than 
the threshold for Medium-sized effects (Cohen’s D = 0.5; Cohen, 1988). In addition, while 
clinical genetic counselors perceived decreased anxiety after genetic counseling regarding DTC 
results, Non-clinical counselors perceived an increase in anxiety after genetic counseling.  
  




Comparison in attitudes toward DTC and patient-initiated testing between clinical and 
non-clinical genetic counselors 
Table 4. Summary of Independent Samples t-tests Comparing Attitudes Towards DTC and patient-initiated Genetic Testing of 
Clinical versus Industry GCs (n = 41-42) 
 
* Levene’s Test for the Equality of Variances revealed a violation of the assumption of equality of variance; degrees of freedom 
were adjusted by SPSS to compensate 
 
In order to compare attitudes toward DTC and patient-initiated testing between clinical 
respondents and non-clinical ones, a series of independent samples t-tests were conducted (see 
Table 4). Only a single comparison emerged as statistically significant; respondents from clinical 
settings more strongly agreed that as DTC and patient-initiated testing options expand, the need 
for genetic counselors is going to increase (all other comparisons p > 0.05). As previously 
discussed, small sample sizes in the non-clinical condition likely undermined the statistical 
power of these analyses, though Cohen’s D values were suggestive, with a couple of 
comparisons approach the benchmark for “medium” sized effects (Cohen’s D = 0.5; Cohen, 
1988).   







This study highlights the value genetic counselors see in pre- and post-test counseling for 
patients, and a general concern about the expansion of patient-initiated testing. Fewer than half 
of genetic counselors surveyed supported consumers being able to self-order clinical testing of 
the ACMG 59 gene list, and even fewer supported consumers being able to self-order larger 
panels. In addition, most counselors felt that pre-test counseling prior to ordering genetic testing 
was necessary to have informed consent, and only 1/3 felt that genetic counseling after receiving 
patient-initiated test results should be optional. This highlights the general impression that 
genetic counseling is important to ensuring that consumers are well informed before and after 
ordering genetic testing. In addition, none of the genetic counselors surveyed felt that consumers 
understand the implications for long-term care, life, and disability insurance before ordering 
patient-initiated testing. Genetic testing can have implications to insurance coverage, which 
consumers should be aware of before ordering testing. Test results may show an increased risk 
for certain types of cancers or diseases, thus impacting coverage. Fewer than 10% of genetic 
counselors agreed that consumers understand the possible results before ordering patient-initiated 
testing, and that consumers understand the health-related implications of a negative result. Fewer 
than 20% of genetic counselors agreed that consumers ordering patient-initiated testing 
understand the health-related implications of a positive result and how patient-initiated test 
results apply to family members. Overall, counselors seem to place significant value on 
consumers being well-informed about the implications of, and possible results from, genetic 
testing. This concern translates to a strong value placed on having consumers meet with a 




genetics specialist who can clearly review family history and provide informed genetic testing 
options, with a review of possible outcomes and results. 
Genetic counselors also generally felt that patients have significant increases in 
understanding the medical significance of DTC results, understanding the limitations of DTC 
testing, understanding how genetic variants can affect health and disease risk, and understanding 
their DTC result reports after genetic counseling regarding DTC results. These increases indicate 
how valuable it can be for consumers to meet with a genetic counselor to discuss DTC results. 
They may learn about additional testing recommendations based on their family history and 
limitations to their current results. Genetic counselors did not express a significant decrease in 
patient anxiety following genetic counseling discussions regarding DTC results, likely because 
patients may learn about the limitations in DTC testing as well as develop a more comprehensive 
understanding of hereditary disease risk based on their family history, which could either 
increase or decrease anxiety. Generally, genetic counselors have observed increases in patient 
knowledge with possible short-term increases or decreases in anxiety surrounding awareness of 
hereditary disease risk.  
While most differences in attitudes toward DTC and patient-initiated testing between 
clinical respondents and non-clinical genetic counselors were not significant, there were some 
interesting differences. Clinical genetic counselors expressed a slightly higher level of concern 
about the expansion of patient-initiated testing and the evolving role of genetic counselors. 
Clinical genetic counselors also expressed higher agreement that DTC and patient-initiated 
testing increased the need for genetic counselors, and this difference was significantly higher 
than that of non-clinical genetic counselors. Clinical genetic counselors may have experiences 
counseling patients who have received DTC or patient-initiated results, that increases their level 




of concern and impression that expansion of genetic testing increases the need for genetic 
counseling.  
It should also be noted that the results of this study are not representative of the genetic 
counseling community as a whole. This sample was heavily skewed towards white, women 
working in clinical settings. The genetic counseling community itself is very limited in its 
diversity as well, being roughly 90% white or Caucasian, 5% Asian, 3% Asian Indian, 1% Black 
or African American, and less than 1% American Indian, Alaskan Native, Native Hawaiian, or 
Other Pacific Islander (National Society of Genetic Counselors, 2019). It is difficult to know 
whether this skewed sample might have different views on patient access to self-testing, as 
compared with a diverse sample that more closely resembles the general population. Future 
research could include more of an effort to recruit non-white subjects, males, and subjects from 
non-clinical settings. For this study, our recruitment involved email distribution to a listserv for 
all members of the NSGC. In future studies, it might be helpful to reach out directly to 
organizations of genetic professionals of color, such as the Minority Genetic Professionals 
Network. 
Although this study did not survey patients directly, it provides possible questions to ask 
as part of a survey of patients before and after counseling sessions. This survey is limited, as 
genetic counselor impressions of patient understanding and feelings surrounding genetic testing 
may not reflect actual changes experienced from a patient’s perspective. We hope that these 
findings can be used to inform future studies that survey patients who have undergone genetic 
counseling before and after receiving DTC or patient-initiated test results. We also hope that 
these questions can be incorporated to compare patient understanding with in-person or 




telegenetic genetic counseling to short information videos or reading materials presented to 
consumers before and after ordering testing.  
 
  







 Overall, this study highlights the value of genetic counseling on patient understanding 
before and after receiving genetic testing results. Interestingly, while genetic counselors 
expressed concerns about the expansion of DTC and patient-initiated testing, direct-to-consumer 
testing has recently declined. When comparing November 2018 to November 2019, direct-to-
consumer genetic testing offered through Ancestry.com declined 38% and 23andMe testing 
declined 54% (Molla, 2020). This may indicate increased awareness amongst consumers of 
privacy concerns and limitations in health-related information offered by this type of testing. We 
also identified some of the values seen in genetic counseling. Respondents felt that patients have 
increases in understanding the medical significance of DTC results, understanding the limitations 
of DTC testing, understanding how genetic variants can affect health and disease risk, and 
understanding their DTC result reports after genetic counseling regarding DTC results. While 
genetic counselors are often involved in psychosocial aspects of counseling, there was not a 
strong perceived decrease in patient anxiety surrounding results following genetic counseling; 
this may be related to a thorough understanding of disease risk provoking a level of anxiety for 
some patients.  
 We have shown the strong value that genetic counselors see in informing patients about 
genetic testing. While this study highlights the importance of informing patients about 
limitations in testing, privacy concerns, and insurance coverage implications, it seems that 
consumers are beginning to pursue these tests with lower frequency. Genetic counseling 
continues to play a valuable role in informing patients about nuances of genetic testing while 
providing individual recommendations for testing. Genetic counselors can help inform patients 




about genetic testing as part of a collaborative team between patients, genetic testing laboratory 
staff, physicians, and medical care providers.   
 
  







Auton, A., Gibbs, R. A., Boerwinkle, E., Doddapaneni, H., Han, Y., Korchina, V., … Rasheed, 
A. (2015). A global reference for human genetic variation. Nature, 526(7571), 68–74. 
Badalato, L., Kalokairinou, L., & Borry, P. (2017). Third party interpretation of raw genetic data: 
an ethical exploration. European Journal of Human Genetics, 25, 1189–1194. 
Bellcross, C. A., Page, P. Z., & Meaney-Delman, D. (2012). Direct-to-consumer personal 
genome testing and cancer risk prediction. The Cancer Journal, 18(4), 293–302. 
Benusiglio, P. R., Di Maria, M., Dorling, L., Jouinot, A., Poli, A., Villebasse, S., … Caron, O. 
(2017). Hereditary breast and ovarian cancer: successful systematic implementation of a 
group approach to genetic counselling. Familial Cancer, 16(1), 51–56. 
Brédart, A., Kop, J.-L., De Pauw, A., Caron, O., Fajac, A., Noguès, C., … Dolbeault, S. (2017). 
Effect on perceived control and psychological distress of genetic knowledge in women with 
breast cancer receiving a BRCA1/2 test result. Breast (Edinburgh, Scotland), 31, 121–127. 
Carere, D. A., Kraft, P., Kaphingst, K. A., Roberts, J. S., & Green, R. C. (2016). Consumers 
report lower confidence in their genetics knowledge following direct-to-consumer personal 
genomic testing. Genetics in Medicine, 18(1), 65–72. 
Carere, D. A., VanderWeele, T., Moreno, T. A., Mountain, J. L., Roberts, J. S., Kraft, P., & 
Green, R. C. (2015). The impact of direct-to-consumer personal genomic testing on 
perceived risk of breast, prostate, colorectal, and lung cancer: Findings from the PGen 
study. BMC Medical Genomics, 8(1), 1–11. 
Christofides, E., & O’Doherty, K. (2016). Company disclosure and consumer perceptions of the 
privacy implications of direct-to-consumer genetic testing. New Genetics and Society, 





Cohen, J. (1988). Statistical Power Analysis for the Behavioral Sciences (2nd ed.). Hillsdale, NJ: 
Lawrence Erlbaum Associates, Publishers. 
Darst, B. F., Madlensky, L., Schork, N. J., Topol, E. J., & Bloss, C. S. (2013). Perceptions of 
genetic counseling services in direct-to-consumer personal genomic testing. Clinical 
Genetics, 84(4), 335–339. 
Dorfman, R. (2013, September 10). Falling prices and unfair competition in consumer genomics. 
Nature Biotechnology. Nature Publishing Group. https://doi.org/10.1038/nbt.2693 
Kalia, S. S., Adelman, K., Bale, S. J., Chung, W. K., Eng, C., Evans, J. P., … Miller, D. T. 
(2017). Recommendations for reporting of secondary findings in clinical exome and 
genome sequencing, 2016 update (ACMG SF v2.0): A policy statement of the American 
College of Medical Genetics and Genomics. Genetics in Medicine, 19(2), 249–255. 
https://doi.org/10.1038/gim.2016.190 
Kirkpatrick, B. E., & Rashkin, M. D. (2017). Ancestry Testing and the Practice of Genetic 
Counseling. Journal of Genetic Counseling, 26, 6–20. 
Koeller, D. R., Uhlmann, W. R., Carere, D. A., Green, R. C., & Roberts, J. S. (2017). Utilization 
of Genetic Counseling after Direct-to-Consumer Genetic Testing: Findings from the Impact 
of Personal Genomics (PGen) Study. Journal of Genetic Counseling, 26(6), 1270–1279. 
Laestadius, L. I., Rich, J. R., & Auer, P. L. (2017). All your data (effectively) belong to us: Data 
practices among direct-to-consumer genetic testing firms. Genetics in Medicine, 19(5), 513–
520. 
Ludwig, K. K., Neuner, J., Butler, A., Geurts, J. L., & Kong, A. L. (2016). Risk reduction and 
survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review. 




American Journal of Surgery, 212(4), 660–669. 
McCuaig, J., Armel, S., Care, M., Volenik, A., Kim, R., Metcalfe, K., … Metcalfe, K. A. (2018). 
Next-Generation Service Delivery: A Scoping Review of Patient Outcomes Associated with 
Alternative Models of Genetic Counseling and Genetic Testing for Hereditary Cancer. 
Cancers, 10(11), 435. 
Middleton, A., Mendes, Á., Benjamin, C. M., & Howard, H. C. (2017). Direct-to-consumer 
genetic testing: Where and how does genetic counseling fit? Personalized Medicine. 
Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., … Ding, 
W. (1994). A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. 
Science (New York, N.Y.), 266(5182), 66–71. 
Molla, R. (2020). 23andMe, Ancestry, and the decline of consumer DNA tests. Vox. Retrieved 
from https://www.vox.com/recode/2020/2/13/21129177/consumer-dna-tests-23andme-
ancestry-sales-decline 
Mullard, A. (2015). 23andMe sets sights on UK/Canada, signs up Genentech. Nature 
Biotechnology, 33(2), 119–119. 
National Comprehensive Cancer Network. (2019). NCCN Guidelines Version 2.2019 Lynch 
Syndrome. Retrieved from 
https://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf 
National Society of Genetic Counselors. (2019). Professional Status Survey. Retrieved from 
https://www.nsgc.org/p/cm/ld/fid=68 
Niemiec, E., Kalokairinou, L., & Howard, H. C. (2017). Current ethical and legal issues in 
health-related direct-to-consumer genetic testing. Personalized Medicine, 14(5), 433–445. 
Phillips, A. M. (2016). Only a click away - DTC genetics for ancestry, health, love...and more: A 




view of the business and regulatory landscape. Applied and Translational Genomics, 8, 16–
22. 
Rahman, N., Seal, S., Thompson, D., Kelly, P., Renwick, A., Elliott, A., … Stratton, M. R. 
(2007). PALB2, which encodes a BRCA2-interacting protein, is a breast cancer 
susceptibility gene. Nature Genetics, 39(2), 165–167. 
Scherr, C. L., Christie, J., & Vadaparampil, S. T. (2016). Breast Cancer Survivors’ Knowledge 
of Hereditary Breast and Ovarian Cancer following Genetic Counseling: An Exploration of 
General and Survivor-Specific Knowledge Items. Public Health Genomics, 19(1), 1–10. 
Tandy-Connor, S., Guiltinan, J., Krempely, K., Laduca, H., Reineke, P., Gutierrez, S., … Davis, 
B. T. (2018). False-positive results released by direct-to-consumer genetic tests highlight 
the importance of clinical confirmation testing for appropriate patient care. Genetics in 
Medicine, 1–7. 
Wooster, R., Neuhausen, S. L., Mangion, J., Quirk, Y., Ford, D., Collins, N., … Averill, D. 
(1994). Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-
13. Science (New York, N.Y.), 265(5181), 2088–2090. 
 
  







Appendix A: Genetic Counselor Survey 
 








































SUPPORT IN NAVIGATING DTC TESTING   40 
 
 
 
 
